Monoclonal Antibody Based Products

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Therapeutics
• Cancer
• Other Therapeutic Mabs
• Diagnostics

II. EXECUTIVE SUMMARY

1. Industry Overview

• World MAb-Based Products Market: A Profile
• MAb Market - Set for Significant Growth
• Therapeutic mAb Market - Principal Driving Force
• Development of New MAbs on a Fast Track
• Genomics Research Leads Way to New Monoclonal Antibodies
• Bright Outlook for MAbs
• Current and Future Analysis
• Regional Perspective
• Product Segment Perspective
• Competitive Scenario
• Intensifying Consolidation Activity
• Table 1: Major Acquisitions of Antibody-Focused Companies (2005-2007)
• Table 2: Leading Players in the Worldwide Monoclonal Antibody Therapy Market (2005): Percentage Breakdown of Sales for Genentech/Roche, J & J/Schering Plough, Abbott Laboratories, MedImmune, ImClone/BMS, and Eli Lilly (includes corresponding Graph/Chart)
• Table 3: Leading Drugs in the Global Therapeutic Monoclonal Antibodies Market (2006): Percentage Breakdown of Dollar Sales for Remicade, Rituxan, Herceptin, Avastin, Humira, Erbitux, Synagis, Xolair and Others (includes corresponding Graph/Chart)
• Table 4: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Manufacturers by Sales for Genentech, Johnson & Johnson, Roche, Abbott, MedImmune, Schering Plough, Eli Lilly, and Others (includes corresponding Graph/Chart)
• Table 5: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Drugs by Sales for Remicade, Rituxan, Herceptin, Synagis, Humira, Avastin, ReoPro, Erbitux, Xolair, and Others (includes corresponding Graph/Chart)
• Table 6: Leading Products in the Global Oncology Monoclonal Antibodies Market (2008E): Percentage Share Breakdown of Sales for Avastin, Herceptin, Rituxan, Erbitux, and Others (includes corresponding Graph/Chart)
• Table 7: Leading Products in the Global Antibody-Based Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues for Enbrel, Remicade, Humira, and Others (includes corresponding Graph/Chart)
• Therapeutic Antibodies in the Market
• Drug Developers Trying to Break the Shackles
• Rituximab Vs. Epratuzumab
• A Revolution Not too Far
• Milestones in Development of MAbs
• Focus on Unmet Medical Needs in the Emerging Markets

2. Industry Analysis

• Evolution of Monoclonal Antibodies - A Historical Journey
• Trends and Issues
• Shift Towards Humanized and Fully Human Antibodies
• Ageing Baby Boomers Spur MAbs Growth
• Non-Existent Generic Competition Favors MAb Market
• Partnerships and Collaborations Spark Increase in Profit Margins
• Pharma Majors & CMOs Augment Investment in Mab Production
• Rising Number of MAbs Under Clinical Trials
• Select Clinical Trials for Monoclonal Antibodies
• Major Monoclonal Antibodies in Phase III Trials Across the World
• High Costs Impede MAbs Penetration
• Opportunities in Technology Development
• Advancements & Challenges in Antibody Production Processes
• Increasing Demand for Protein A in Mab Manufacturing
• FCA- A Major Cause for Discomfort in Mice
• Innovations to Drive Growth in Anti-Ovarian Cancer Drugs Market
• Rising Incidence of NHL to Drive Monoclonal Antibody Drug Market

3. Product Overview

• Immune System: Natural Defenders
• Human Antibodies
• Antibodies Offer Natural Immunity
• Induction of The Immune Process
• Mechanism of Action
• Polyclonal and Monoclonal Antibodies
• Production of Monoclonal Antibodies
• Traditional Methods
• The Hybridoma Technology
• Separation and Purification of Monoclonals
• Factors Impacting Production of MAbs
• Types of Monoclonal Antibodies
• Table 8: Worldwide MAb Market by Product Type (2008): Percentage Share Breakdown for Chimeric, Humanized, Human and Murine (includes corresponding Graph/Chart)
• Murine Monoclonal Antibodies
• Humanized Antibodies/ CDR Grafted Antibodies
• Murine Vs Human Monoclonal Antibodies
• Chimeric Antibodies: Show Lesser Antigenicity
• Fully Human Antibodies
• Bispecific Antibodies
• Certain Limitations Do Exist
• Advantages of MAbs
• Advantages and Limitations of MAb Technologies

4. Diagnostic Applications of Monoclonal

• Monoclonal Antibody Based Diagnostics
• Immunodiagnostics
• Monoclonals Used as Targeting Agents
• Radio labeled Monoclonal Antibodies for Diagnostic Imaging
• The Pros and Cons of MAb-Based Immunoconjugates
• Cytogen: The First to Introduce A Monoclonal Antibody-based Cancer Agent
• NeoProbe' s Radioimmunogzuided Surgery
• Cancer
• A Historical Overview
• Initial Hiccups
• Tumor Markers

5. Monoclonal Antibody-Based Therapeutics

• Evolution of Therapeutic Antibody Products
• Advantages of Therapeutic Monoclonal Antibodies
• Current Scenario in Monoclonal Antibody Therapeutics Market
• Table 9: Monoclonal Antibody Market by Therapy Area (2004 & 2010): Percentage Breakdown by Sales for Oncology, Arthritis, Immune & Inflammatory Disorders, Infectious Diseases, Cardiovascular, Respiratory, Ophthalmology, and CNS (includes corresponding Graph/Chart)
• Cancer Therapeutics
• Monoclonal Antibodies Offer Hope Against Cancer
• Monoclonal Antibodies Approved For Cancer Treatment in the World
• Monoclonal Antibody Cancer Therapies Under Development
• Antibody Therapies for Cancer
• Cancer: A Serious Issue and Plaguing Illness Worldwide
• Breast Cancer: The Most Common Form of Cancer in American Women
• Breast Cancer - Treatment Options
• Monoclonal Antibodies Against NHL
• Monoclonal Antibodies Against Ovarian Cancer
• MAb Immunotherapy - Effective for Residual Ovarian Cancer
• Melanoma
• Immunologic Effector Functions
• Colorectal Cancer: Rising Incidence
• Panorex: The First Cancer Therapeutic in the Market
• Myeloid Leukemia

6. Other Therapeutic Monoclonal Antibodies

• Therapeutic Monoclonal Antibody Drugs and Applications
• MAbs used in Clinical Field
• Inflammation Therapeutics
• Inflammation
• Asthma: A Chronic Affliction
• Autoimmune Diseases
• What Goes Wrong
• Intervention Better Than Prevention
• Some Autoimmune Diseases
• Multiple Sclerosis
• Crohn' s Disease
• Rheumatoid Arthritis
• Organ Transplantation
• Biology of Transplantation
• Types of Transplants
• Autografts
• Syngeneic Transplants
• Allografts
• Xenografts
• Follow-up Treatment
• Products to Counter Rejection
• OKT3: A Monoclonal Already in the Market
• Infectious Diseases
• Sepsis
• A Rapid Process
• Gram Negative Bacteria are the Causative Agents
• A Retrospect
• Monoclonal Antibodies and Septic Shock
• HIV/AIDS
• What is AIDS?
• Global Statistics
• HIV/AIDS Testing
• Monoclonal Antibodies and HIV
• Cardiovascular
• Cardiovascular Diseases are Fatal
• Treatment Options
• Causes of Cardiovascular Diseases
• ReoPro

7. Regulation Impacting The Industry

• Regulations in the U.S
• Approval: A Laborious Process
• Clinical Trials
• Orphan Drug Status

8. Research and Development Activities

• Rituxan and Herceptin from Genentech
• FuCell hybridomas
• Test-tube MAbs/ Phase Display Library
• Rituxan for Cancer Treatment
• GenMAb Develops Fully Human Antibodies
• Protein Design Labs Licenses Trioma
• Protein Design Labs' Innovative Technology

9. Product Launches and Developments

• Amgen Introduces Vectibix
• Trevigen Introduces Mouse Monoclonal Antibody
• UCB Receives FDA Approval for Cimzia(r)
• GSK' s Tykerb Receives FDA Approval
• Dr. Reddy' s Introduces Reditux(tm)
• Morphotek Receives Orphan Drug Status for MORAb - 009 mAb
• Biocon Introduces BIOMab Monoclonal Antibody
• Biotest AG and AERES Biomedical Develop BT- 062
• Genentech Launches Avastin
• Biotest Unveils Intratect(r)
• Genentech Introduces Xolair
• Genentech Unveils Raptiva
• Corixa Presents BEXXAR
• IGEN Launches Monoclonal Antibody Therapies
• MAb Against Pseudomonas Aeruginosa
• Wyeth Introduces Mylotarg

10. Recent Industry Activity

• EUSA Pharma to Take Over Cytogen
• AVANIR Inks a Definitive Agreement to Divest Anthrax Antibodies
• Access Pharmaceuticals Acquires Somanta Pharmaceuticals
• Daiichi Sankyo to Take Over U3 Pharma
• IMUC Completes Molecular Antibody Technology Acquisition
• Callisto Merger Corporation Merges with Celldex Therapeutics
• Genmab Enters into Antibody Research Collaboration with Pepscan
• BTI Enters into an Agreement with Raven
• Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104
• Eusa Sells Antibody Research Business
• CG Therapeutics and UoW Agree for Joint Monoclonal Antibody Program
• Raven and CMC ICOS Collaborate to Advance RAV18
• SDI to Develop mAbs for SAIC-F and NCI
• HGS Reacquires Rights for TRAIL Receptor Antibodies
• CAT Grants Exclusive Worldwide License of CAT-213 to iCo
• Morphotek and HMI in Licensing Agreement
• Amgen Enters into Licensing Agreement with Kyowa Hakko
• Dyax and Sanofi-Aventis Sign Agreements
• HGS Enters into Antibody Collaboration Agreement with Xencor
• CSL Limited Inks a Collaboration Agreement with Celltrion
• Eisai Acquires Morphotek
• Astellas US Holding Takes Over Agensys
• Astrazeneca Creates New Integrated Business Unit - Medimmune
• Genentech Acquires Tanox
• Biotest Acquires Assets of Nabi Biologics
• CMC Acquires ICOS Biologics Operation
• Roche Takes Over THP
• GTC and LFB Commence CD20 Monoclonal Antibody Development
• Regeneron Grants a Non-Exclusive License to AstraZeneca
• OncoMed Enters into Monoclonal Antibody Deal with GSK
• BioArctic and Eisai Announce Licensing Agreement
• MediGene Collaborates with Celltrion
• Amgen Inks Collaboration and License Pact with Daiichi Sankyo
• CMC Biopharmaceuticals Inks Agreement with Morphotek
• CMC Biopharmaceuticals Inks Agreement with Biotest
• Eli Lilly Collaborates with MacroGenics
• Genentech Inks Global Licensing Agreement with Seattle Genetics
• VaxGen to Merge with Raven Biotechnologies
• Abeome Enters into Distribution Agreement with Millipore
• Compugen Forays into Monoclonal Antibody Business
• MilleGen and LFB Enter into Partnership Agreement
• Favrille Acquires Diversa' s Anti-CD20 Monoclonal Antibodies
• Kirin Inks Licensing Agreement with Astellas Pharma
• Viropro in Partnership with NRC-BRI
• Merck Acquires Abmaxis
• Micromet Merges with CancerVax
• Tanabe & Janssen Team Up to Develop Anti-TNF Alpha Monoclonal Antibody
• Intercell Enters into Strategic Alliance with Kirin
• Xencor Extends R&D Collaboration with Roche
• MedImmune Inks Licensing Agreement with Japan Tobacco
• Immunomedics Enters into an Agreement with UCB for Epratuzumab
• Akorn and Serum Institute Enter into Development and Distribution Agreement
• FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen
• LSP Acquires Global License for Monoclonal Antibodies from Ludwig Institute
• Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug Candidates
• EU Grants Orphan Drug Designation to GPC' s Anticancer Monoclonal Antibody
• Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer Treatment
• Amgen Takes Over Abgenix
• Celera and Medarex in Strategic Alliance for Developing Human Monoclonal Antibody Therapeutics
• UCB Collaborates with Immunomedics
• Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business
• Roche Licenses Rabbit Monoclonal Antibody Technology from Epitomics
• BioGenex Receives FDA Pre-Market Approval for InSite(tm) Monoclonal Antibody
• Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal Antibody
• XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal Antibodies
• HGS Bags Two-Phase Contract for ABthrax(tm) Mab from the US Government
• Medarex and PharmAthene Receive Funding for Development of Valortim(tm)
• UCB Collaborates with Millenium
• MorphoSys Acquires Two Antibody Technology Companies
• Tanabe Seiyaku and Remicade Sign Addendum
• Abgenix Receives Royalty from Human Genome
• Amgen Acquires Tularik
• Sunesis Pharmaceuticals Collaborates with Biogen Idec
• H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics
• EMBL and Abnova Inks Collaboration Agreement
• AstraZeneca and CAT in Five-Year Strategic Alliance for Monoclonal Antibody Research
• UCB Acquires Celltech
• ImmunoGen Signs Licensing Agreement with Biogen
• Lonza Inks MAbs Manufacturing and Supply Agreement with NovImmune
• Avanir and Peregrine Sign License Agreement
• BioVest Concludes Agreement with Bioventix
• Roche to Set Up Two Manufacturing Facilities in Switzerland
• XTL Biopharm Bags European patent for Human Monoclonal Anti Body
• MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials
• Health Canada Approves HUMIRA

11. Industry Activity in the Recent Past (2000-2003)

• CAT Signs Licensing Agreement with Micromet
• CAT Enters into Agreement with Genzyme
• Medarex and Avlon Enter into Agreement
• Micromet, Enzon and CAT Sign Cross-License Agreement
• Xerion and CAT Enter into Agreement
• Genetastix and Nissho Enter into Agreement
• InNexus and Corixa Enter into Agreement
• Abbott Collaborates with LigoCyte
• CAT Acquires Drug Royalty Corporation
• CAT and Amrad Join Hands for Research
• IDEC' s Receives FDA Approval for Zevalin
• Medarex Enters into Research Alliance with Seattle Genetics
• Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody
• Eos, Medarex and Biosite in Alliance for Cancer Treatment
• Imgenex forms Alliance with GMO
• CAT and Elan Enter into Strategic Alliance
• Bioinvent International Enters into Agreement with Novo Nordisk for Drug Discovery Research
• Epicyte and Dow Chemical Enter into Agreement
• Rockland Announces the Completion of Laboratory Expansion
• Roche' s MAbThera Receives Approval in Japan
• Aviva Launches Manufacturing and Marketing Operations
• ICOS and Seattle Enters into Joint Development and Manufacturing Agreement
• Medarex and Corixa Team-up to Develop Human Monoclonal Antibodies
• Taisho Enters into Research Alliance with IDEC
• PDL Signs Agreement with InterMune
• ProMetic Signs Agreement with Integrated Protein
• Medarex Signs Agreement with ZynloGenetics
• CAT Joins Hands with GD. Searle
• Medarex and MedImmune Enter into Antibody Research Agreement
• Lonza Signs Agreement with ImClone Systems
• MedImmune and Alkermes Enter into Agreement
• GTC and Abgenix Enter into Production Agreement
• Genzyme Transgenics Expands Agreement with Centocor
• PDL and InterMune Enter into an Agreement

12. Focus on Select Global Players

• Amgen, Inc. (US)
• BD Biosciences (US)
• Biogen Idec Inc (US)
• Biotest AG (Germany)
• CMC ICOS Biologics, Inc.
• Dendreon Corporation (US)
• Elan Corporations Plc (Ireland)
• Eli Lilly and Company (US)
• Genentech, Inc. (USA)
• Human Genome Sciences, Inc. (US)
• Immunomedics (US)
• Johnson & Johnson (US)
• Centocor (US)
• Ortho Biotech Products, L.P. (US)
• Medarex, Inc. (US)
• MedImmune, Inc. (US)
• PDL BioPharma (US)
• Schering-Plough Corporation (US)
• Strategic Diagnostics Inc (US)
• UCB Group (Belgium)
• Wyeth Pharmaceuticals (US)

13. Global Market Perspective

• Table 10: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 11: World Long-term Projections for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 12: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 13: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 14: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 15: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 16: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment - Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 17: World Long-term Projections for Therapeutic Monoclonal Antibody Based Products by Segment - Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 18: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments - Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2003, 2008 & 2012
• Table 19: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 20: World Long-term Projections for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 21: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 22: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 23: World Long-term Projections for Other (*) Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 24: World 10-Year Perspective for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 25: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 26: World Long-term Projections for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 27: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The Untied States

• A. Market Analysis
  • Global Hub of MAbs
  • Approved Therapeutic Antibodies in the US (As of 2007)
  • Therapeutic Monoclonal Antibodies Market - An Overview
  • New Heights f or US Cancer Therapeutics
  • Competitive Landscape
  • Leading Products
  • Table 28: Leading Products in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Breakdown of Revenues for Remicade, Avastin, Rituxan, Herceptin, Synagis, Lucentis, Erbitux, and Others (includes corresponding Graph/Chart)
  • Table 29: Leading Players in the US Therapeutic Monoclonal Antibodies Market (2007): Percentage Share Breakdown of Revenues for Genentech Inc, Centocor, MedImmune, Bristol Meyer' s Squibb, Amgen, Hoffman-La Roche, and Others (includes corresponding Graph/Chart)
  • Focus on Key Players
  • Amgen, Inc.
  • BD Biosciences
  • Biogen Idec.
  • CMC ICOS Biologics, Inc.
  • Dendreon Corporation
  • Eli Lilly and Company
  • Genentech, Inc.
  • Human Genome Sciences
  • Immunomedics
  • Johnson & Johnson
  • Centocor
  • Ortho Biotech Products, L.P.
  • Medarex, Inc.
  • MedImmune, Inc
  • PDL BioPharma
  • Schering-Plough Corporation
  • Strategic Diagnostics Inc
  • Wyeth Pharmaceuticals
  • Product launches
  • Strategic Developments
• B. Market Analytics
  • Table 30: US Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 31: US Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 32: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 33: Canadian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 34: Canadian Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 35: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 36: Japanese Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010, (includes corresponding Graph/Chart)
  • Table 37: Japanese Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 38: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Biotechnology and Pharmacy Research
  • Monoclonal Antibody Based Products Market in Europe
  • European Therapeutic MAbs Market - An Overview
  • Approved Therapeutic Antibodies in Europe as of 2004
  • Need to Reduce Complexities, Time & Cost of mAb Development
  • Information Dissemination - Critical for Enhancing mAb Sales
  • Monoclonal Antibody Immunotherapy for NHL
  • MabThera - A Dominant MAb Drug in Europe
  • Emerging Radioimmunotherapy Products
  • Challenges for New Drug Development
• B. Market Analytics
  • Table 39: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Geographic Region - France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 40: European Long-term Projections for Monoclonal Antibody Based Products by Geographic Region - France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 41: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 42: European Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 43: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region -Percentage Breakdown of Dollar Sales for France, Germany, Italy, The UK, and Rest of Europe for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 44: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Strategic Developments
• B. Market Analytics
  • Table 45: French Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 46: French Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 47: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• A. Market Analysis
  • Biotest AG- A Key Player
  • Product Launches
  • Strategic Developments
• B. Market Analytics
  • Table 48: German Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 49: German Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 50: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. Italy

• Market Analysis
• Table 51: Italian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
• Table 52: Italian Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 53: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. The United Kingdom

• A. Market Analysis
  • Monoclonal Antibodies Market - An Overview
  • Strategic Developments
  • Product Launches
• B. Market Analytics
  • Table 54: UK Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 55: UK Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 56: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Rest of Europe

• A. Market Analysis
  • Key Players
  • Elan Corporations Plc (Ireland)
  • UCB Group (Belgium)
  • Strategic Developments
• B. Market Analytics
  • Table 57: Rest of Europe Market for Monoclonal Antibody Based Products - Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 58: Rest of Europe Long-term Projections for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 59: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Rest of World

• A. Market Analysis
  • Australia
  • India
  • Strategic Developments
• B. Market Analytics
  • Table 60: Rest of World Market for Monoclonal Antibody Based Products - Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart)
  • Table 61: Rest of World (*) Market for Monoclonal Antibody Based Products - Long-term Projections by Product Segment for Therapeutics (Cancer and Others), and Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 62: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE